In a promising stride toward AI-driven preventive healthcare, Aptar Digital Health and AstraZeneca have joined forces to pioneer the development of groundbreaking screening algorithms for chronic, underdiagnosed conditions starting with chronic kidney disease (CKD). This new collaboration could redefine how some of the most elusive and dangerous diseases are identified, intervened upon, and ultimately managed.
At the heart of this initiative lies a revolutionary concept: early detection of CKD through the eyes. Building on AstraZeneca’s extensive research and robust AI capabilities, the screening tool taps into fundus imaging a routine eye exam enhancing it with advanced machine learning algorithms to pick up subtle biomarkers and indicators of renal stress long before symptoms become clinically obvious. With CKD impacting up to 16% of the global population and frequently flying under the radar, this approach brings much-needed attention to one of the world’s silent killers.
Aptar Digital Health, known for its patient-centric digital solutions, is now stepping into a deeper realm of diagnostics. By licensing AstraZeneca’s proprietary algorithms, the company aims to scale access to this AI-based tool, particularly in primary care settings where early intervention can be most impactful. As Gael Touya, President of Aptar Pharma, put it: “This partnership enables Aptar to harness AI for disease detection in ways that are non-invasive, scalable, and genuinely transformative.”
What’s more, this innovation has the potential to expand beyond CKD. The algorithmic model could be adapted to detect a spectrum of cardiovascular, renal, and metabolic disorders, offering a broader early warning system embedded in common clinical workflows.
Romain Marmot, President of Aptar Digital Health, emphasized the larger goal: “It’s about improving the patient journey by empowering clinicians with earlier, smarter tools. Early diagnosis enables timely treatment, which translates directly into better outcomes.”
For AstraZeneca, this is another leap in its growing focus on integrating diagnostics and therapeutics to combat non-communicable diseases. Mina Makar, SVP at AstraZeneca, said it best: “This collaboration is about delivering scalable, sustainable solutions that meet one of healthcare’s biggest challenges undiagnosed chronic kidney disease.”
As development progresses, the solution will undergo clinical validation, with a view toward integration across health systems, ophthalmic hardware, and even pharmaceutical partnerships. It’s not just an algorithm it’s a new chapter in precision screening for the people who need it most.